PerkinElmer buys imaging firm VisMed

PerkinElmer has acquired Bedford, MA-based molecular imaging technology company VisEn Medical for an undisclosed sum. According to PerkinElmer exec Richard Eglen, VisEn's molecular imaging platforms complements PE's existing cellular imaging business by boosting the company's preclinical research offerings. "This acquisition broadens our product portfolio along the drug discovery pipeline, from basic disease-based research to preclinical drug discovery applications, through the addition of proprietary chemistries in the emerging and fast growing space of translational biomarker reagents," Eglen said in a statement.

VisEn Fluorescence Agent Portfolio and its Fluorescence Molecular Tomographic (FMTTM) Imaging Systems can help researchers identify disease biomarkers and therapeutic efficacy in cells and animal models. PerkinElmer hopes that combining VisEn's technology with its existing business will lead to better screening of new drugs. VisEn's fluorescence molecular imaging systems and reagents are currently being used for cancer, inflammation, cardiovascular, skeletal and pulmonary disease research.

- here's the PerkinElmer release
- get more from Xconomy

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.